Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berberine for low HDL-C
ChiCTR2200056694Phase 4Not yet recruiting
- Sponsor
- Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of berberine in Hypo-HDL cholesterolemia (HALP) and primary dyslipidaemia, sponsored by Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine. Primary endpoint: High-density lipoprotein cholesterol at week 12. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
berberine
03
Conditions
Hypo-HDL cholesterolemia (HALP)primary dyslipidaemia
Beyond the preview
Go deeper on ChiCTR2200056694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056694.